Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 in Refractory GIST
NCT01404650Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Dec 2011
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Luminespib in gastrointestinal stromal tumor (GIST), sponsored by SCRI Development Innovations. Primary endpoint: Progression-Free Survival up to 4 years. Started Dec 2011; status: completed.
02
Drugs
Luminespib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT01404650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01404650.